Ultrapotent topical corticosteroid treatment of childhood genital lichen sclerosus.
OBJECTIVE
To observe the clinical effects of short-term application of ultrapotent topical corticosteroid on symptomatic genital lesions of lichen sclerosus in pediatric patients.


METHODS
Case series of 10 prepubertal girls with genital lichen sclerosus. Ultrapotent topical corticosteroids were applied twice daily for 6 to 8 weeks and patients were reexamined at completion of treatment. Long-term follow-up over 6 months to 3 years.


METHODS
Pediatric dermatology clinic (referral center).


METHODS
Ten prepubertal girls with typical clinical features of genital and/or perianal lichen sclerosus.


METHODS
Topical ultrapotent corticosteroid ointment was applied sparingly to affected areas for 6 to 8 weeks.


METHODS
Improvement of erythema, whitening erosions, and atrophy. Subjective improvement of symptoms.


RESULTS
All patients showed partial or total subsistence of signs and symptoms of lichen sclerosus. Frequency and severity of recurrences varied, but patients responded within a few days to reapplication of ultrapotent topical corticosteroid. No significant adverse effects were noted after the initial 6- to 8-week course of therapy or during the 6-month to 3-year follow-up period.


CONCLUSIONS
A 6- to 8-week course of ultrapotent topical corticosteroid is a safe and effective treatment for genital lichen sclerosus in pediatric patients.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005938:Glucocorticoids; D006801:Humans; D018459:Lichen Sclerosus et Atrophicus / Q000188:drug therapy*